Paul Fields

Adaptive Biotechnologies (United States) — United States

Medicine · Health Sciences

28h-index4.4kcitations121works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(48), Virus-based gene therapy research(35), Immunotherapy and Immune Responses(30), SARS-CoV-2 and COVID-19 Research(14), COVID-19 Clinical Research Studies(12)

Publications121 total

Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity
npj Vaccines·2026Open Access
Pre-transplant T-cell clonal analysis identifies CD8+ donor reactive clones that contribute to kidney transplant rejection
Frontiers in Immunology·2025· 2 citedOpen Access
Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels
Frontiers in Immunology·2025· 7 citedOpen Access
COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort
UNC Libraries·2024Open Access
COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort
Science Advances·2024· 3 citedOpen Access
Supplementary Figure S2 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Table S3 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Figure S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Table S3 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Methods S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Table S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Table S2 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Data from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Table S2 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Figure S3 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Figure S4 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Table S1 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Figure S4 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Data from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
Supplementary Table S4 from Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Roland W. Herzog(8), Katherine A. High(8), Harlan Robins(7), Valder R. Arruda(7), Lil Pabon(6), Charles E. Murry(6), Linda B. Couto(5), J. Nathan Hagstrom(5), Alessandro Bertero(5), Laurie A. Boyer(4), Hans Reinecke(4), William Stafford Noble(4), Lauren E. Surface(3), Melissa Burton(3), Timothy C. Nichols(3), Ian M. Kaplan(3), Ralph S. Baric(3), Rachel M. Gittelman(3), Giancarlo Bonora(3), Jay Shendure(3)